UTILITY PATENT APPLICATION **TRANSMITTAL**

Under the Paperwork Reduction Act of 1995, no persons are required to res

(Only for new nonprovisional applications under 37 CFR 1.53(b))

pond to a collection of informa	filloff unless it displays a valid Olvid Control it	uiline
Attorney Docket No.	13/112	
First Inventor	Murray D. Bailey	
Title	Hepatits C Inhibitor Peptide Analogs	2
Express Mail Label No.	EL 989311258 US	9.0

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.	ADDRESS TO: Mail stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450					
Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing) Applicant claims small entity status. See 37 CFR 1.27. Specification [Total Pages 63] (preferred arrangement set forth below) - Descriptive title of the invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed)	7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Form (CRF) b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or ii. Paper c. Statements verifying identity of above copies					
- Detailed Description - Claim(s) - Abstract of the Disclosure	ACCOMPANYING APPLICATION PARTS					
4. □ Drawing(s) (35 U.S.C. 113) [Total Sheets □] 5. Oath or Declaration [Total Sheets □] a. □ Newly executed (original or copy) b. □ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed) i. □ DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) name in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 6. ✔ Application Data Sheet. See 37 CFR 1.76 18. If a CONTINUING APPLICATION, check appropriate box, and suppose specification following the title, or in an Application Data Sheet under 30 □ Continuation □ Divisional □ Divisional □ Continuation □ Divisional □ Divisi	ation-in-part (CIP) of prior application No.:					
19. CORRESPON	IDENCE ADDRESS					
Customer Number: 28513	OR Correspondence address below					
Name						
Address						
City	State Zip Code					
Country	Telephone Fax					
Name (Print/Type) Philip I. Datlow Signature	Registration No. (Attorney/Agent) 41,482 Date March 2, 2004					

This collection of information is required by CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE	TR	AN	SMI	T	TAL
ı	for	FY	200	4	

Effective 10/01/2003. Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

(\$)	1	23	8.	00
------	---	----	----	----

Complete if Known				
Application Number	Not Yet Assigned			
Filing Date	March 2, 2004			
First Named Inventor	Murray D. Bailey			
Examiner Name	Not Yet Assigned			
Art Unit	Not Yet Assigned			
Attorney Docket No.	13/112			

METHOD OF PAYMENT (check all that apply)			FEE CALCULATION (continued)						
Check Credit card Money Other None		3. ADDITIONAL FEES							
Deposit Account:			Large Entity Small Entity						
Denosit		Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid		
Account Number			1051	130	2051		Surcharge - late filing fee or oath		
Deposit Account	Boehring	jer Ingelheim Corpo	oration	1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
Name The Director is	s authorized t	o: (check all that apply)		1053	130	1053		Non-English specification	———
Charge fee			verpayments	1812	2,520	1812	2,520	For filing a request for ex parte reexamination	<u> </u>
Charge any	y additional fee	(s) or any underpayment of	fee(s)	1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
<u> </u>	e(s) indicated be dentified deposi	elow, except for the filing	fee	1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
to the above-io				1251	110	2251	55	Extension for reply within first month	
4 54005		CALCULATION		1252	420	2252	210	Extension for reply within second month	
1. BASIC F Large Entity \$	Small Entity			1253	950	2253	475	Extension for reply within third month	
Fee Fee	Fee Fee	Fee Description	Fee Paid	1254	1,480	2254	740	Extension for reply within fourth month	
Code (\$) 1001 770	Code (\$) 2001 385	Utility filing fee		1255	2,010	2255	1,005	Extension for reply within fifth month	
1002 340	2002 170	Design filing fee	770.00	1401	330	2401	165	Notice of Appeal	
1003 530	2003 265	Plant filing fee	\vdash	1402	330	2402	165	Filing a brief in support of an appeal	
1004 770	2004 385	Reissue filing fee		1403	290	2403	145	Request for oral hearing	
1005 160	2005 80	Provisional filing fee		1451	1,510	1451	1,510	Petition to institute a public use proceeding	
	١,	SUBTOTAL (1) (\$)	770.00	1452	110	2452	55	Petition to revive - unavoidable	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE		1453	1,330	2453	665	Petition to revive - unintentional			
2. EXTRA (CLAIM FEE	S FOR UTILITY AND Fee fro	m	1501	1,330	2501	665	Utility issue fee (or reissue)	
Total Claims 46 -20** = 26 × 18.00 = 468.00		1502	480	2502	240	Design issue fee			
			1503	640	2503	320	Plant issue fee		
Claims Multiple Depe		** = <u>0</u> x <u>86.00</u> 290.00		1460	130	1460	130	Petitions to the Commissioner	
				1807	50	1807	7 50	Processing fee under 37 CFR 1.17(q)	
Large Entity Fee Fee	Small Entity	L Fee Description		1806	180	1806		Submission of Information Disclosure Stmt	
Code (\$)	Code (\$)			8021	40	8021	1 40	Recording each patent assignment per property (times number of properties)	
1202 18 1201 86	2202 9 2201 43	9 Claims in excess of 203 Independent claims in excess.	excess of 3	1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1203 290	2203 14		•	1810	770	2810	385	For each additional invention to be examined (37 CFR 1.129(b))	
1204 86	2204 4:	3 ** Reissue independen over original patent	Cams	1801	770	2801	385	` ''	
1205 18	2205 9	** Reissue claims in ex and over original pate		1802	900	1802	900	Request for expedited examination of a design application	
469.00			Other fee (specify)						
SUBTOTAL (2) (\$) 400.00 **or number previously paid, if greater; For Reissues, see above			*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$)						
					-				

(Complete (if applicable)) SUBMITTED BY Registration No. Name (Print/Type) Philip I. Datlow 41,482 Telephone 203-798-4542 (Attorney/Agent) March 2, 2004 Date Signature

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete. including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

APPLICANT(S):

M. D. BAILEY, et al.

SERIAL NO.:

Not Yet Assigned

CONFIRMATION NO.: FILING DATE: Ma

O.: Not Yet Assigned March 2, 2004

DOCKET NO.:

13/112

TITLE:

Hepatitis C Inhibitor Peptide Analogs

- 1. Utility Patent Application Transmittal (1 pg);
- 2. Fee Transmittal (1 pg, in Triplicate);
- 3 Application Data Sheet (3pgs);
- 4. Specification (63 pgs)
- 5. Sequence Listing (1 pg)

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road P.O. Box 368

Ridgefield, CT 06877-0368

Tel: (203) 798-4542 Date: March 2, 2004 "EXPRESS MAIL" LABEL NO.: EL 989311258 US

DEPOSIT DATE: March 2, 2004

I HEREBY CERTIFY THAT THE ABOVE PAPERS AND FEE ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO:

Commissioner for Patents Mail Stop Patent Application P. O. Box 1450 Alexandria, VA 22313-1450

Philip 1. Datlow Reg. No. 41,482